- Home
- WOLF vs IMTX Comparison
WOLF vs IMTX Comparison
Compare WOLF & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOLF | IMTX |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WOLF | IMTX |
|---|---|---|
| Price | $27.28 | $9.14 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $14.33 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 3.1M | 586.8K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $1.20 | $5.67 |
| 52 Week High | $80.82 | $12.41 |
Technical Indicators
Market Signals| Indicator | WOLF | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 47.98 |
| Support Level | $15.61 | $8.56 |
| Resistance Level | $35.18 | $10.32 |
| Average True Range (ATR) | 2.03 | 0.44 |
| MACD | 0.36 | 0.02 |
| Stochastic Oscillator | 62.56 | 58.39 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.